Denali Therapeutics Inc.
DNLI- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001714899
In the last 90 days, Denali Therapeutics Inc. insiders filed 0 open-market purchases and 4 sales; 294 institutions reported holding it in 13F filings for Q2 2026, worth $4.00B in total; no superinvestor holds it.
Holders of 5% or more of DNLI
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Denali Therapeutics Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Baillie Gifford & Co | 13G/A | 8.60%12.3M shares | – | Feb 12, 20251 filing | Feb 12, 2025 | SEC |
| BlackRock, Inc. | 13G/A | 7.20%10.5M shares | – | Apr 17, 20251 filing | Apr 17, 2025 | SEC |
| FMR LLC | 13G/A | 5.80%8.54M shares | – | Nov 5, 20251 filing | Nov 5, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
6 Schedule 13D and 13G filings on Denali Therapeutics Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Mar 26, 20266:06 PM ET | Vanguard Group Inc | 13G/A | 0.00%0 shares | –Below 5% | Mar 13, 2026 | SEC |
| Nov 5, 202511:30 AM ET | FMR LLCand 1 other | 13G/A | 5.80%8.54M shares | – | Sep 30, 2025 | SEC |
| Aug 12, 202510:34 AM ET | Wellington Management Group LLPand 2 others | 13G/A | 3.90%5.66M shares | –Below 5% | Jun 30, 2025 | SEC |
| Apr 17, 20253:05 PM ET | BlackRock, Inc. | 13G/A | 7.20%10.5M shares | – | Mar 31, 2025 | SEC |
| Feb 13, 20252:14 PM ET | Capital Research Global Investors | 13G/A | 3.80%5.48M shares | –Below 5% | Dec 31, 2024 | SEC |
| Feb 12, 202510:52 AM ET | Baillie Gifford & Co | 13G/A | 8.60%12.3M shares | – | Dec 31, 2024 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Denali Therapeutics Inc. shares.
No Form 144 notices for Denali Therapeutics Inc. are on file.